24 июл. 2024 г. · Lenacapavir reduced HIV incidence by 100% as compared with background HIV incidence (incidence rate ratio, 0.00; 95% CI, 0.00 to 0.04; P<0.001) ...

26 сент. 2024 г. · Lenacapavir demonstrated a 96% reduction in HIV incidence compared to background HIV incidence (2.37 per 100 person-years) and was 89% more ...

The PURPOSE studies provide new information about HIV prevention through testing a new, twice-yearly injectable medicine, the investigational drug ...

This phase 2 study was designed to generate exploratory clinical data of lenacapavir-containing regimens, either as part of three-drug or two-drug regimens. The ...

12 сент. 2024 г. · Lenacapavir reduced HIV infections by 96% compared to background HIV incidence (bHIV). There were 2 incident cases among 2,180 participants, ...

Selected Study Results: Results presented at HIVR4P 2024 showed that among the participants who received twice-yearly lenacapavir injections, 99.9% of ...

11 мая 2022 г. · In a phase 1b study, lenacapavir showed substantial antiviral activity. ... In the ongoing phase 3 CAPELLA trial, we assessed the efficacy and ...

20 июн. 2024 г. · Study participants were randomized in a 2:2:1 ratio to lenacapavir, Descovy and Truvada, respectively. Because effective PrEP options already ...

26 июн. 2024 г. · The injectable antiretroviral drug lenacapavir was safe and 100% effective as long-acting HIV pre-exposure prophylaxis (PrEP) among ...

Prior to that, the PURPOSE 1 study demonstrated that lenacapavir reduced HIV acquisitions by 100% and demonstrated superiority to daily F/TDF ...